WuXi NextCODE is a global platform for genomic data. It will use the funds to extend platform infrastructure as well as gain new users and data. It will focus on precision medicine and diagnostics partnerships and the commercialization of its consumer solutions for the China market. WuXi NextCODE’s capabilities span study design, sequencing, scalable analytics as well as artificial intelligence and deep learning.
“We plan to continue to push the leading edge of technology for digitizing, managing and analyzing genomic big data, including through our path-breaking AI, and to put it at the service of ever more enterprises, institutions, and individuals around the world,” said Hannes Smarason, CEO of WuXi NextCODE.
More articles on data analytics & precision medicine:
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant
University of Rochester Medical Center taps NextGate to aggregate provider data
Startup Insider: 4 questions with 2bPrecise CEO Assaf Halevy
